Methitest Side Effects
Generic name: methyltestosterone
Note: This document contains side effect information about methyltestosterone. Some of the dosage forms listed on this page may not apply to the brand name Methitest.
Some side effects of Methitest may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to methyltestosterone: oral capsule, oral tablet
Get emergency medical help if you have any of these signs of an allergic reaction while taking methyltestosterone (the active ingredient contained in Methitest) hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:
feeling short of breath, even with mild exertion;
swelling, rapid weight gain;
increased or ongoing erection of the penis;
bone pain, increased thirst, memory problems, restless feeling, confusion, nausea, loss of appetite, increased urination, weakness, muscle twitching; or
nausea, vomiting, stomach pain, loss of appetite, and jaundice (yellowing of the skin or eyes).
Women receiving methyltestosterone may develop male characteristics, which could be irreversible if testosterone treatment is continued. Stop taking this medication and call your doctor at once if you notice any of these signs of excess testosterone:
changes in menstrual periods;
male-pattern hair growth (such as on the chin or chest);
hoarse voice; or
Less serious side effects (in men or women) may include:
acne, changes in skin color;
male pattern baldness;
headache, anxiety, depressed mood;
numbness or tingly feeling; or
increased or decreased interest in sex.
This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect.
For Healthcare Professionals
Applies to methyltestosterone: compounding powder, oral capsule, oral tablet
Cardiovascular effects have included edema (with and without congestive heart failure).
Endocrine side effects have included gynecomastia. Cautious use is recommended in patients with existing gynecomastia.
During exogenous administration of androgens, endogenous testosterone release is inhibited through feedback inhibition of pituitary luteinizing hormone (LH). Large doses of exogenous androgens may suppress spermatogenesis through inhibition of pituitary follicle stimulating hormone (FSH).
Androgens may decrease levels of thyroxine-binding globulin resulting in decreased total T4 serum levels and increased resin uptake of T3 and T4. Free thyroid hormone levels remain unchanged and there is no clinical evidence of thyroid dysfunction.
Renal side effects have included retention of nitrogen, sodium, potassium, chloride, water, and phosphorus and decreased urinary excretion of calcium. Patients should be instructed to report edema.
Hepatic side effects have included life-threatening peliosis hepatitis and hepatic abnormalities including hepatic neoplasms and hepatocellular carcinomas following prolonged therapy with high doses of androgen. Tumor regression did not occur in all cases following medication withdrawal.
Cholestatic hepatitis, jaundice, and abnormal liver function tests have occurred during androgen therapy. Drug-induced jaundice is reversible following drug discontinuation.
Genitourinary side effects have included oligospermia and decreased ejaculatory volume following chronic administration and/or large dosages of androgens. Elderly male patients may experience prostatic enlargement resulting in urinary obstruction. Priapism and excessive stimulation may develop. Methyltestosterone should be discontinued if any of these effects occur. If continued therapy is necessary, resume methyltestosterone (the active ingredient contained in Methitest) at a lower dosage.
In female patients the use of androgens has resulted in virilization, including deepening voice, hirsutism, acne, clitomegaly (not reversible), and menstrual abnormalities. Discontinuation of methyltestosterone at signs of mild virilization may prevent irreversible virilization.
Metabolic side effects have included osteolytic-induced hypercalcemia in immobilized patients or those with metastatic breast disease.
Androgens affect electrolyte balance, nitrogen retention, and urinary calcium excretion. Edema, with and without congestive heart failure has occurred during testosterone therapy.
Androgens have precipitated acute intermittent porphyria.
Increased cholesterol levels have occurred during androgen therapy.
Dermatologic side effects have included hirsutism, acne, male-patterned baldness and seborrhea.
Gastrointestinal side effects have included nausea and vomiting.
Testosterone is involved in termination of linear bone growth by closure of the epiphyseal growth centers. Monitoring of bone age is recommended during methyltestosterone (the active ingredient contained in Methitest) treatment in healthy males with delayed puberty.
Myalgia and pain have been reported.
Hematologic side effects have included alteration in clotting factors II, V, VII and X and polycythemia due to increased red cell production.
Hypersensitivity side effects have included rare reports of rash and anaphylactoid reactions.
Local side effects have included inflammation and pain at injection or dermal application site.
Nervous system side effects have included altered libido (increased/decreased), headache, anxiety, depression, generalized paresthesia, or sleep apnea syndrome.
Oncologic side effects have included hepatic neoplasms and hepatocellular carcinomas following prolonged therapy with large doses of androgens.
Respiratory side effects have included potentiation of sleep apnea, particularly in obese patients or those with chronic lung disease. Androgen therapy for hypogonadal conditions has been reported to
Other side effects have included virilization including deepening voice, hirsutism, acne, clitomegaly (not reversible), and menstrual abnormalities in female patients. Discontinuation of methyltestosterone (the active ingredient contained in Methitest) at signs of mild virilization may prevent irreversible virilization.
More Methitest resources
- Methitest Concise Consumer Information (Cerner Multum)
- Methitest Prescribing Information (FDA)
- Android MedFacts Consumer Leaflet (Wolters Kluwer)
- Android Prescribing Information (FDA)
- Methyltestosterone Professional Patient Advice (Wolters Kluwer)
- Methyltestosterone Monograph (AHFS DI)
- Testred Prescribing Information (FDA)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.